Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

PaperCitations, authors & open-access status

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 418 citations, 2019 year and bronze oa status.

418
Citations
2019
Year
bronze
OA Status

Related on ScholarIQ

Helena A. Yu
Author
Mark G. Kris
Author
Gregory J. Riely
Author
Matthew D. Hellmann
Author
Annals of Oncology
Journal
Cancer Immunotherapy and Biomarkers
Topic
470M+ articles · free account